This week, eight biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
Cancer Genetics, Inc. (CGIX) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. In Portfolio Grader’s specific subcategories of Earnings Revisions and Sales Growth, CGIX also gets A’s. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. For more information, get Portfolio Grader’s complete analysis of CGIX stock.
La Jolla Pharmaceutical Company (LJPC) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of LJPC stock.
Incyte Corporation (INCY) improves from a C to a B rating this week. Incyte is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. For more information, get Portfolio Grader’s complete analysis of INCY stock.
Ambit Biosciences Corp. (AMBI) earns a B this week, jumping up from last week’s grade of C. For more information, get Portfolio Grader’s complete analysis of AMBI stock.
GTx, Inc. (GTXI) improves from a C to a B rating this week. GTx discovers, develops, and commercializes therapeutics primarily related to the treatment of serious men’s health conditions. For more information, get Portfolio Grader’s complete analysis of GTXI stock.
This week, Progenics Pharmaceuticals, Inc. (PGNX) pushes up from a C to a B rating. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. For more information, get Portfolio Grader’s complete analysis of PGNX stock.
This is a strong week for Celladon Corporation (CLDN). The company’s rating climbs to A from the previous week’s B. For more information, get Portfolio Grader’s complete analysis of CLDN stock.
Kite Pharma, Inc. (KITE) gets a higher grade this week, advancing from a B last week to an A. For more information, get Portfolio Grader’s complete analysis of KITE stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
